Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for Non-small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer. In recent years, immunotherapy has developed rapidly. Immune checkpoint inhibitors, especially programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors have made a breakthrough in the treatment of N...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2019-07-01
|
| Series: | Chinese Journal of Lung Cancer |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2019.07.06 |
| _version_ | 1818477768727330816 |
|---|---|
| author | Sixuan WU Chunhong HU Fang WU Yuanqiang WU Ping LIU |
| author_facet | Sixuan WU Chunhong HU Fang WU Yuanqiang WU Ping LIU |
| author_sort | Sixuan WU |
| collection | DOAJ |
| description | Non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer. In recent years, immunotherapy has developed rapidly. Immune checkpoint inhibitors, especially programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors have made a breakthrough in the treatment of NSCLC and changed the treatment pattern for NSCLC. Immunological checkpoint inhibitors targeting PD-1/PD-L1 are beneficial to patients, both in the first-line and second-line treatment of advanced NSCLC, in the adjuvant treatment of locally-advanced NSCLC, and in the neoadjuvant therapy of early NSCLC, which show an important role in the comprehensive treatment of NSCLC. This article reviews the clinical research progress of immunological checkpoint inhibitors targeting PD-1/PD-L1 in NSCLC. |
| first_indexed | 2024-12-10T09:41:08Z |
| format | Article |
| id | doaj.art-48b7d04ff2f240beb5c0d80e128fc68b |
| institution | Directory Open Access Journal |
| issn | 1009-3419 1999-6187 |
| language | zho |
| last_indexed | 2024-12-10T09:41:08Z |
| publishDate | 2019-07-01 |
| publisher | Chinese Anti-Cancer Association; Chinese Antituberculosis Association |
| record_format | Article |
| series | Chinese Journal of Lung Cancer |
| spelling | doaj.art-48b7d04ff2f240beb5c0d80e128fc68b2022-12-22T01:53:59ZzhoChinese Anti-Cancer Association; Chinese Antituberculosis AssociationChinese Journal of Lung Cancer1009-34191999-61872019-07-0122744044810.3779/j.issn.1009-3419.2019.07.06Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for
Non-small Cell Lung CancerSixuan WU0Chunhong HU1Fang WU2Yuanqiang WU3Ping LIU4Department of Oncology, the Second Xiangya Hospital, Central South University, Changsha 410011, ChinaDepartment of Oncology, the Second Xiangya Hospital, Central South University, Changsha 410011, ChinaDepartment of Oncology, the Second Xiangya Hospital, Central South University, Changsha 410011, ChinaDepartment of Oncology, the Second Xiangya Hospital, Central South University, Changsha 410011, ChinaDepartment of Oncology, the Second Xiangya Hospital, Central South University, Changsha 410011, ChinaNon-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer. In recent years, immunotherapy has developed rapidly. Immune checkpoint inhibitors, especially programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors have made a breakthrough in the treatment of NSCLC and changed the treatment pattern for NSCLC. Immunological checkpoint inhibitors targeting PD-1/PD-L1 are beneficial to patients, both in the first-line and second-line treatment of advanced NSCLC, in the adjuvant treatment of locally-advanced NSCLC, and in the neoadjuvant therapy of early NSCLC, which show an important role in the comprehensive treatment of NSCLC. This article reviews the clinical research progress of immunological checkpoint inhibitors targeting PD-1/PD-L1 in NSCLC.http://dx.doi.org/10.3779/j.issn.1009-3419.2019.07.06Lung neoplasmsCancer immunotherapyPD-1/PD-L1Immune checkpoint inhibitor |
| spellingShingle | Sixuan WU Chunhong HU Fang WU Yuanqiang WU Ping LIU Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for Non-small Cell Lung Cancer Chinese Journal of Lung Cancer Lung neoplasms Cancer immunotherapy PD-1/PD-L1 Immune checkpoint inhibitor |
| title | Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for
Non-small Cell Lung Cancer |
| title_full | Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for
Non-small Cell Lung Cancer |
| title_fullStr | Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for
Non-small Cell Lung Cancer |
| title_full_unstemmed | Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for
Non-small Cell Lung Cancer |
| title_short | Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for
Non-small Cell Lung Cancer |
| title_sort | progress in clinical researches of pd 1 pd l1 checkpoint inhibitor for
non small cell lung cancer |
| topic | Lung neoplasms Cancer immunotherapy PD-1/PD-L1 Immune checkpoint inhibitor |
| url | http://dx.doi.org/10.3779/j.issn.1009-3419.2019.07.06 |
| work_keys_str_mv | AT sixuanwu progressinclinicalresearchesofpd1pdl1checkpointinhibitorfornonsmallcelllungcancer AT chunhonghu progressinclinicalresearchesofpd1pdl1checkpointinhibitorfornonsmallcelllungcancer AT fangwu progressinclinicalresearchesofpd1pdl1checkpointinhibitorfornonsmallcelllungcancer AT yuanqiangwu progressinclinicalresearchesofpd1pdl1checkpointinhibitorfornonsmallcelllungcancer AT pingliu progressinclinicalresearchesofpd1pdl1checkpointinhibitorfornonsmallcelllungcancer |